The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Autologous Serum Tears Receives High Patient Satisfaction Scores for Dry Eye Disease

Autologous Serum Tears Receives High Patient Satisfaction Scores for Dry Eye Disease

August 27, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Treatments for dry eye disease include artificial tears with and without preservatives, cyclosporine 0.05% eye drops, compounded cyclosporine 1–2% eye drops, steroid eye drops, lubricating gel drops, eye ointment and punctual plugs. Ophthalmologists consider the use of autologous serum tears as a second- line treatment for autoimmune conditions and a third-line treatment for severe dry eye disease. Specifically, the Dry Eye Workshop II Management and Therapy Report states autologous serum tears are a therapeutic option in step three of the staged management and treatment recommendation for dry eye.1

You Might Also Like
  • New Options for Patients with Concurrent Dry Eye & Rheumatic Disease
  • Lacrimal & Tear Fluid Yield Clues to Dry Eye Disease
  • Patient Satisfaction Scores—Do They Matter?
Also By This Author
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels

Recent research supporting this recommendation found that patients with severe dry eyes benefit from autologous serum tears treatment, experiencing reduced symptoms. The treatment also received high patient satisfaction scores. The paper by Mohammed Kreimei, MD, an ophthalmologist at the University of Toronto, Canada, and colleagues was published online July 2 in The Ocular Surface.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“To the best of our knowledge, our study is the first in the literature to directly evaluate patients’ satisfaction with [autologous serum tears] by using the validated [Treatment Satisfaction Questionnaire for Medication (TSQM)] questionnaire,” they write.

The study focused on patient satisfaction because patients’ perspectives of their disease can affect patient health-related quality of life, functional disability and disease outcome. “Patients’ satisfaction was assessed using the standardized, validated TSQM,” write the authors in their discussion. “The TSQM was designed as a general measure of treatment satisfaction with medication and is suitable for use across a wide variety of treatment modalities and illness conditions.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The prospective, observational case-series included 100 participants who had received treatment with autologous serum tears for varying amounts of time: 25% were treated for 1–6 months, 24% for 6–12 months, 22% for 1–2 years and 29% for 2–3 years. The mean age of patients was 61.5 ± 15.6 years and 70% were female. The mean cumulative five-item Dry Eye Questionnaire (DEQ-5) score was 12.7 ± 3.8, and a majority of participants (65%) scored greater than 12, suggesting an underlying diagnosis of Sjögren’s syndrome. The researchers also measured the patients’ perspective using the Symptom Assessment in Dry Eye (SANDE) Questionnaire. The survey study did not include a control group.

The Results
After patients began treatment with autologous serum tears, they experienced a significant decrease in the use of other treatments and their mean total SANDE score improved from 79.5 ± 21.8 before to 42.2 ± 23.2 after use of autologous serum tears. The mean TSQM scores were 73.1 ± 17.2 (efficacy), 72.5 ± 17.5 (convenience) and 74.6 ± 22.7 (global satisfaction). None of the patients reported any side effects.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: autologous serum tears, Dry eye, eye, Eye disease, patient satisfaction, Sjögren's syndrome

You Might Also Like:
  • New Options for Patients with Concurrent Dry Eye & Rheumatic Disease
  • Lacrimal & Tear Fluid Yield Clues to Dry Eye Disease
  • Patient Satisfaction Scores—Do They Matter?
  • How Rheumatologists Can Improve Patients’ Satisfaction, Patient Care, and Survey Scores

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.